Sunday, March 07, 2021 4:12:41 AM
Good Day Hindukush!Glad to see you are still so active with substantive posts giving both meaning and context to an often emotional discussion.
What I do not understand is this:
on this board there are a lot of our members here which are substantial shareholders. I recall a certain plastic surgeon owning in the vicinity of a million shares or so..
I presume that the accumulated share count represented here would well exceed 5% of the total shares outstanding which is substantial. With all the legal experts on board here why not team up and form an activist shareholders interest group that bundles its voting rights to make an impact on company policies?
For instance re: Lovaza - I recall that this argument about the detrimental impact of its EPA/DHA formulation already being a hot topic here for at least 4 years. But how can we have it being brought up on the BoD agenda instead of just churning it here again and again.
Or is it just a convenient way to express pent up frustration on the abysmal performance of the share price.
I admire the action that you and @Marjac and @BioBill have taken to right the wrongs due to Du being conned with false evidence.
Can we get a little more a proactive on other issues also as a united special interest shareholder group with some legal framework to be recognized as a united voting block?
What I do not understand is this:
on this board there are a lot of our members here which are substantial shareholders. I recall a certain plastic surgeon owning in the vicinity of a million shares or so..
I presume that the accumulated share count represented here would well exceed 5% of the total shares outstanding which is substantial. With all the legal experts on board here why not team up and form an activist shareholders interest group that bundles its voting rights to make an impact on company policies?
For instance re: Lovaza - I recall that this argument about the detrimental impact of its EPA/DHA formulation already being a hot topic here for at least 4 years. But how can we have it being brought up on the BoD agenda instead of just churning it here again and again.
Or is it just a convenient way to express pent up frustration on the abysmal performance of the share price.
I admire the action that you and @Marjac and @BioBill have taken to right the wrongs due to Du being conned with false evidence.
Can we get a little more a proactive on other issues also as a united special interest shareholder group with some legal framework to be recognized as a united voting block?
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
